Aadi Bioscience - AADI Stock Forecast, Price & News

1 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Aadi Bioscience in the last twelve months. There are currently 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" AADI shares.
View AADI analyst ratings or view top-rated stocks.

1 analysts have issued 1 year price targets for Aadi Bioscience's stock. Their AADI share price forecasts range from $30.00 to $48.00. On average, they anticipate the company's stock price to reach $41.67 in the next twelve months. This suggests a possible upside of 454.1% from the stock's current price.
View analysts price targets for AADI or view top-rated stocks among Wall Street analysts.

Aadi Bioscience's stock was trading at $12.83 on January 1st, 2023. Since then, AADI shares have decreased by 41.4% and is now trading at $7.52.
View the best growth stocks for 2023 here.

Aadi Bioscience saw a increase in short interest in the month of February. As of February 28th, there was short interest totaling 1,180,000 shares, an increase of 6.3% from the February 13th total of 1,110,000 shares. Based on an average daily trading volume, of 104,500 shares, the short-interest ratio is currently 11.3 days. Approximately 7.3% of the company's shares are short sold.
View Aadi Bioscience's Short Interest.

The company is scheduled to release its next quarterly earnings announcement on Tuesday, March 28th 2023.
View our AADI earnings forecast.

Aadi Bioscience will be holding an earnings conference call on Tuesday, March 28th at 8:30 AM Eastern. Interested parties can register for or listen to the call using this link.

Aadi Bioscience, Inc. (NASDAQ:AADI) announced its quarterly earnings results on Tuesday, August, 10th. The company reported ($0.68) earnings per share (EPS) for the quarter, beating the consensus estimate of ($3.00) by $2.33. Aadi Bioscience had a negative trailing twelve-month return on equity of 44.28% and a negative net margin of 569.57%.

ALPS Medical Breakthroughs ETF holds 16,567 shares of AADI stock, representing 0.13% of its portfolio.

Aadi Bioscience shares reverse split on the morning of Friday, August 27th 2021. The 1-15 reverse split was announced on Thursday, August 26th 2021. The number of shares owned by shareholders was adjusted after the market closes on Wednesday, August 25th 2021. An investor that had 100 shares of stock prior to the reverse split would have 7 shares after the split.

Aadi Bioscience trades on the NASDAQ under the ticker symbol "AADI."

Aadi Bioscience's stock is owned by a number of retail and institutional investors. Top institutional investors include Alerce Investment Management L.P. (6.68%), Geode Capital Management LLC (1.07%), Opaleye Management Inc. (1.03%), Renaissance Technologies LLC (1.03%), Price T Rowe Associates Inc. MD (1.01%) and ExodusPoint Capital Management LP (0.31%). Insiders that own company stock include Caley Castelein, Neil Desai and Orbimed Advisors Llc.
View institutional ownership trends.

Shares of AADI stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of AADI stock can currently be purchased for approximately $7.52.

Aadi Bioscience (NASDAQ:AADI) has a market capitalization of $183.49 million and generates $1.12 million in revenue each year. The company earns $-110,090,000.00 in net income (profit) each year or ($2.98) on an earnings per share basis.

Aadi Bioscience's mailing address is 9987 Carver Rd, Blue Ash, Ohio 45242-5550. The official website for the company is aadibio.com. The company can be reached via phone at (424) 473-8055 or via email at ikoffler@lifesciadvisors.com.